文献速递生殖医学

构建竞争性内源RNA网络以识别多囊卵巢综合征的药物靶点

Construction of a competing endogenous RNA network to identify drug targets against polycystic ovary syndrome.
PubMed 文献 · Hum Reprod · 2022-01-01

本研究通过生物信息学分析五组人颗粒细胞微阵列数据构建竞争性内源RNA(ceRNA)网络,并用24例女性(12例多囊卵巢综合征(PCOS)患者和12例对照)的黄素化颗粒细胞样本进行实时定量PCR验证。研究发现10个mRNA、11个miRNA和53个lncRNA差异表达,构建了由2个lncRNA、2个miRNA和5个mRNA组成的ceRNA网络,并预测出二甲双胍等已获批药物可能靶向网络中的分子。

要点

  • 构建了由2个lncRNA、2个miRNA和5个mRNA组成的ceRNA网络。
  • 功能富集分析显示与免疫系统相关生物学过程和信号通路高度相关。
  • 预测出二甲双胍等已获批药物可能靶向网络中的分子作为PCOS候选药物。

核心结论

  • 结合生物信息学方法与临床样本分析,基于所建立的ceRNA网络可识别美国食品药品监督管理局(FDA)已批准药物和候选药物。

研究设计与样本

  • 生物信息学部分纳入五组人颗粒细胞微阵列数据构建ceRNA网络。
  • 人群验证部分于2021年1月至2021年7月收集24例有无PCOS女性的样本,包括12例无PCOS女性和12例PCOS女性的黄素化颗粒细胞样本。

主要发现

  • 共10个mRNA、11个miRNA和53个长链非编码RNA(lncRNA)差异表达。
  • 功能富集分析显示与免疫系统相关生物学过程和信号通路(如细胞因子分泌和白细胞趋化)相关性最高。
  • 构建了由2个lncRNA、2个miRNA和5个mRNA组成的ceRNA网络。
  • 通过生物信息学网络构建识别出一些已获批药物(如二甲双胍)可靶向网络中的某些分子,作为PCOS的潜在候选药物。

局限性

  • 需要在细胞和动物模型系统中测试所识别候选药物之前,通过免疫沉淀、荧光素酶报告基因实验和动物模型研究等实验验证ceRNA网络中的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Would the construction of a competing endogenous RNA (ceRNA) network help identify new drug targets for the development of potential therapies for polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Both Food and Drug Administartion (FDA)-approved and candidate drugs could be identified by combining bioinformatics approaches with clinical sample analysis based on our established ceRNA network. WHAT IS KNOWN ALREADY: Thus far, no effective drugs are available for treating PCOS. ceRNAs play crucial roles in multiple diseases, and some of them are in current use as prognostic biomarkers as well as for chemo-response and drug prediction. STUDY DESIGN, SIZE, DURATION: For the bioinformatics part, five microarrays of human granulosa cells were considered eligible after applying strict screening criteria and were used to construct the ceRNA network for target identification. For population-based validation, samples from 24 women with and without PCOS were collected from January 2021 to July 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: The public data included 27 unaffected women and 25 women with PCOS, according to the Rotterdam criteria proposed in 2003. The limma and RobustRankAggreg R packages were used to identify differentially expressed messenger RNAs and noncoding RNAs. Gene Ontology, Reactome and Kyoto Encyclopedia of Genes and Gemomes (KEGG) enrichment analyses were performed. A ceRNA network was constructed by integrating the differentially expressed genes and target genes. The population-based validation included human luteinized granulosa cell samples from 12 unaffected women and 12 women with PCOS. Quantitative real-time polymerase chain reaction was conducted to detect the levels of mRNAs and microRNAs (miRNAs). Connectivity map and computational model algorithms were implemented to predict therapeutic drugs from the ceRNA network. Additionally, we compared the predicted drugs with known clinical medications in DrugBank. MAIN RESULTS AND THE ROLE OF CHANCE: A set of 10 mRNAs, 11 miRNAs and 53 long non-coding RNAs (lncRNAs) were differentially expressed. Functional enrichment analysis revealed the highest relevance to immune system-related biological processes and signalling pathways, such as cytokine secretion and leucocyte chemotaxis. A ceRNA consisting of two lncRNAs, two miRNAs and five mRNAs was constructed. Through network construction via bioinformatic analysis, we identified some already approved drugs (such as metformin) that could target some molecules in the network as potential drug candidates for PCOS. LARGE SCALE DATA: Public sequencing data were obtained from GSE34526, GSE84376, GSE102293, GSE106724 and GSE114419, which have been deposited in the Gene Expression Omnibus database. LIMITATIONS, REASONS FOR CAUTION: Experiments, such as immunoprecipitation, luciferase reporter assays and animal model studies, are needed to validate the potential targets in the ceRNA network before the identified drug candidates can be tested using cellular and animal model systems. WIDER IMPLICATIONS OF THE FINDINGS: Our findings provide new bioinformatic insight into the possible pathogenesis of PCOS from ceRNA network analysis, which has not been previously studied in the human reproductive field. Our study also reveals some potential drug candidates for the future development of possible therapies against PCOS. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by grants from the National Key Research and Development Program of China (2021YFC2700400) and the National Natural Science Foundation of China (82001498). The authors have no conflicts of interest to disclose.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Wu T, Gao YY, Tang XN, et al. Construction of a competing endogenous RNA network to identify drug targets against polycystic ovary syndrome. Hum Reprod. 2022. PMID: 36223608. doi:10.1093/humrep/deac218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。